The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

ETHealthworld.com brings latest pulmonary arterial hypertension news, views and updates from all top sources for the Indian Health industry.

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

SQL injection vulnerabilities occur when an attacker can interfere with the queries that an application makes to its database. You can use Burp to test for these vulnerabilities: Professional Use Burp ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

In oncology drugs, Keytruda sales are likely to have been ... is likely to have hurt sales of neuromuscular blockade medicine — Bridion injection. The Zacks Consensus Estimate for Bridion ...